WASHINGTON DCâ€”Patients with metastatic breast cancer who are HER-2 positive could potentially be treated with the anti-HER-2 conjugated drug, trastuzumab-emtansine (T-DM1), alone â€” without needing to add chemotherapy. This prediction was made at the American Association for Cancer Research annual conference by Dr Jose Baselga Physician in Chief at New Yorkâ€™s Memorial Sloan-Kettering Cancer Center on the basis of data the EMILIA study (which led to the approval of this agent in the USA in 2013). He gave Peter Goodwin details about the effectiveness of this new agent in the presence of PI-3 kinase mutations.
You may also like...
Can Initial Radiotherapy Improve Survival with Prostate Cancer? 20 Jul, 2018 Adjuvant Checkpoint Inhibition Extends Disease-Free and Overall Survival in Patients with Stage III Melanoma 13 Oct, 2016 HAND2 gene: key to endometrial, ovarian cancer detection and treatment individualisation 15 Jan, 2014 Radiotherapy Triggers Durable Immunotherapy Responsiveness Beyond Radiation Field 24 Aug, 2016
- Previous story Two-step immunotherapy brings promise in advanced ovarian cancer
- Next story Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014